Physician profile
James A Jacob
NPI 1760489884
$4,220.18
in general payments reported to CMS, 2019-2025
20 companies · $227 in 2025
The $227 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $259 · 2021: $843 · 2022: $988 · 2023: $1,051 · 2024: $469 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,734 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,734.22 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,232.17 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $316.69 | 2019-2024 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $286.14 | 2021-2023 | Xifaxan, Plenvu |
| Janssen Biotech, INC. | $274.49 | 2019-2024 | Stelara, Simponi Aria, Simponi |
| Daiichi Sankyo INC. | $218.98 | 2023-2024 | Injectafer |
| Nestle Healthcare Nutrition INC. | $197.12 | 2021-2023 | |
| Gilead Sciences, INC. | $165.86 | 2019-2023 | |
| Pfizer INC. | $147.22 | 2019-2023 | |
| Aimmune Therapeutics, INC. | $69.13 | 2024 | |
| Genzyme Corporation | $58.04 | 2022 | |
| Ironwood Pharmaceuticals, INC | $48.04 | 2021-2023 | Linzess |
| Mallinckrodt Hospital Products INC. | $32.98 | 2023 | Terlivaz |
| Shire North American Group INC | $30.51 | 2019 | |
| Braintree Laboratories, INC. | $27.73 | 2021-2022 | |
| Laborie Medical Technologies Corp. | $27.52 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $21.42 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $20.83 | 2023 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $18.44 | 2023 | |
| Redhill Biopharma INC. | $16.05 | 2020 | |
| Ucb, INC. | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Jacob listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.